BlackRock Discloses 5.0% Passive Stake in X4 Pharmaceuticals
Ticker: XFOR · Form: SC 13G · Filed: Jan 31, 2024 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | SC 13G |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, biotech
TL;DR
**BlackRock just revealed a 5.0% passive stake in X4 Pharmaceuticals as of year-end 2023.**
AI Summary
BlackRock Inc., a major investment firm, reported owning 5.0% of X4 Pharmaceuticals, Inc.'s Common Stock as of December 31, 2023. This translates to BlackRock holding 1,364,742 shares. This filing indicates BlackRock's significant, but passive, stake in the biotech company, which could be seen as a vote of confidence from a large institutional investor for current and prospective shareholders.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant stake in X4 Pharmaceuticals, which can signal stability and institutional interest to other investors.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces volatility and doesn't suggest immediate risks.
Analyst Insight
Investors should note BlackRock's passive 5.0% stake as a sign of institutional interest, but recognize it's a passive holding, not an active management role. This could provide a baseline of support for the stock.
Key Numbers
- 1,364,742 — Shares Owned (Total number of Common Stock shares BlackRock Inc. beneficially owns in X4 Pharmaceuticals, Inc.)
- 5.0% — Ownership Percentage (Percentage of X4 Pharmaceuticals, Inc.'s Common Stock owned by BlackRock Inc.)
Key Players & Entities
- BlackRock Inc. (company) — filing as the reporting person, holding shares of X4 Pharmaceuticals
- X4 Pharmaceuticals, Inc. (company) — the subject company whose shares are being reported
- 1,364,742 (dollar_amount) — number of shares of Common Stock beneficially owned by BlackRock Inc.
- 5.0% (dollar_amount) — percentage of class of Common Stock beneficially owned by BlackRock Inc.
- December 31, 2023 (person) — date of the event which required the filing of this statement
Forward-Looking Statements
- BlackRock will maintain its passive stake in X4 Pharmaceuticals for the foreseeable future. (BlackRock Inc.) — medium confidence, target: Q2 2024
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person in this SC 13G filing is BlackRock Inc., as indicated in the 'FILED BY' section and the cover page.
What is the subject company whose shares are being reported?
The subject company is X4 Pharmaceuticals, Inc., as stated in the 'SUBJECT COMPANY' section and the 'Name of Issuer' on the Schedule 13G form.
As of what date did the event requiring this filing occur?
The event requiring this filing occurred on December 31, 2023, as specified under 'Date of Event Which Requires Filing of this Statement'.
How many shares of X4 Pharmaceuticals, Inc. Common Stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 1,364,742 shares of X4 Pharmaceuticals, Inc. Common Stock, as per the filing details.
What percentage of X4 Pharmaceuticals, Inc.'s Common Stock does BlackRock Inc. own?
BlackRock Inc. owns 5.0% of X4 Pharmaceuticals, Inc.'s Common Stock, as reported in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 31, 2024 by December 31, 2023 regarding X4 Pharmaceuticals, Inc (XFOR).